161 related articles for article (PubMed ID: 38332637)
1. Identification and validation of a glycolysis-related taxonomy for improving outcomes in glioma.
Ying T; Lai Y; Lu S; E S
CNS Neurosci Ther; 2024 Feb; 30(2):e14601. PubMed ID: 38332637
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a personalized classifier to predict the prognosis and response to immunotherapy in glioma based on glycolysis and the tumor microenvironment.
Fan P; Xia J; Zhou M; Zhuo C; He H
PeerJ; 2023; 11():e16066. PubMed ID: 37744243
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a two glycolysis-related LncRNAs prognostic signature for glioma and in vitro analyses.
Xu X; Zhou S; Tao Y; Zhong Z; Shao Y; Yi Y
Cell Div; 2023 Jun; 18(1):10. PubMed ID: 37355624
[TBL] [Abstract][Full Text] [Related]
4. Identification of Four Metabolic Subtypes of Glioma Based on Glycolysis-Cholesterol Synthesis Genes.
Zhang J; Xiao X; Guo Q; Wei Z; Hua W
Comput Math Methods Med; 2022; 2022():9448144. PubMed ID: 35242216
[TBL] [Abstract][Full Text] [Related]
5. A Prognostic Model for Brain Glioma Patients Based on 9 Signature Glycolytic Genes.
Bingxiang X; Panxing W; Lu F; Xiuyou Y; Chao D
Biomed Res Int; 2021; 2021():6680066. PubMed ID: 34222480
[TBL] [Abstract][Full Text] [Related]
6. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
[No Abstract] [Full Text] [Related]
7. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
8. Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma.
Zhang S; Chen S; Wang Z; Li J; Yuan Y; Feng W; Li W; Chen M; Liu Y
Front Pharmacol; 2022; 13():1061597. PubMed ID: 36386216
[TBL] [Abstract][Full Text] [Related]
9. A pyroptosis-related signature predicts prognosis and indicates immune microenvironment infiltration in glioma.
Chen J; Chen S; Li B; Zhou S; Lin H
Cancer Med; 2023 Feb; 12(4):5071-5087. PubMed ID: 36161280
[TBL] [Abstract][Full Text] [Related]
10. Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.
Li P; Wang S; Wan H; Huang Y; Yin K; Sun K; Jin H; Wang Z
Front Immunol; 2024; 15():1258475. PubMed ID: 38352883
[TBL] [Abstract][Full Text] [Related]
11. A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma.
Luo C; Wang S; Shan W; Liao W; Zhang S; Wang Y; Xin Q; Yang T; Hu S; Xie W; Xu N; Zhang Y
Front Immunol; 2022; 13():909189. PubMed ID: 35769464
[TBL] [Abstract][Full Text] [Related]
12. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
Xu Y; Sun X; Liu G; Li H; Yu M; Zhu Y
Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
[TBL] [Abstract][Full Text] [Related]
13. Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy.
Chen S; Zhang S; Feng W; Li J; Yuan Y; Li W; Wang Z; Yang Y; Liu Y
Front Pharmacol; 2022; 13():1072253. PubMed ID: 36467068
[TBL] [Abstract][Full Text] [Related]
14. Alteration in glycolytic/cholesterogenic gene expression is associated with bladder cancer prognosis and immune cell infiltration.
Zhang Y; Zhu B; Cai Y; Zhu S; Zhao H; Ying X; Jiang C; Zeng J
BMC Cancer; 2022 Jan; 22(1):2. PubMed ID: 34980012
[TBL] [Abstract][Full Text] [Related]
15. Targeting glycometabolic reprogramming to restore the sensitivity of leukemia drug-resistant K562/ADM cells to adriamycin.
Zhang X; Chen J; Ai Z; Zhang Z; Lin L; Wei H
Life Sci; 2018 Dec; 215():1-10. PubMed ID: 30473023
[TBL] [Abstract][Full Text] [Related]
16. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment.
Jiang Z; Liu Z; Li M; Chen C; Wang X
EBioMedicine; 2019 Apr; 42():431-442. PubMed ID: 30935888
[TBL] [Abstract][Full Text] [Related]
17. Construction and experimental validation of a signature for predicting prognosis and immune infiltration analysis of glioma based on disulfidptosis-related lncRNAs.
Guo Y; Jiang Z; Chen Q; Xie D; Zhou Y; Yin W; Wang Z; Wang B; Ren C; Jiang X
Front Immunol; 2023; 14():1291385. PubMed ID: 38022537
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of a glycolysis and cholesterol synthesis-related genes signature for predicting prognosis and immune landscape in osteosarcoma.
Xu F; Yan J; Peng Z; Liu J; Li Z
Front Immunol; 2022; 13():1096009. PubMed ID: 36618348
[TBL] [Abstract][Full Text] [Related]
19. Based on disulfidptosis-related glycolytic genes to construct a signature for predicting prognosis and immune infiltration analysis of hepatocellular carcinoma.
Wang Z; Chen X; Zhang J; Chen X; Peng J; Huang W
Front Immunol; 2023; 14():1204338. PubMed ID: 37680641
[TBL] [Abstract][Full Text] [Related]
20. Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma.
Zhang N; Zhang H; Wu W; Zhou R; Li S; Wang Z; Dai Z; Zhang L; Liu F; Liu Z; Zhang J; Luo P; Liu Z; Cheng Q
Theranostics; 2022; 12(13):5931-5948. PubMed ID: 35966587
[No Abstract] [Full Text] [Related]
[Next] [New Search]
